Quantitative structure-activity relationships of Ca2 + -antagonistic semotiadil congeners

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 3, 1996, Pages 542-546

  Fujimura, Ken Ichi ^a   Ota, Atsutoshi ^a   Kawashima, Yoichi ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Calcium antagonist; Dipole moment; Free energy; Lipophilicity; Quantitative structure activity relationships; Semotiadil

Indexed keywords

BENZOTHIAZINE DERIVATIVE; CALCIUM ANTAGONIST; SESAMODIL FUMARATE;

ARTICLE; CALCIUM ANTAGONISM; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; GUINEA PIGS; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 0029926940     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.542     Document Type: Article

References (21)

1. a)Fujita M., Ito S., Ota A., Kato N., Yamamoto K., Kawashima Y., Yamauchi H., Iwao J., J. Med. Chem , 33, 1898-1905 (1992)
2. b) Nishimura K., Miyawaki N., Yamauchi H., Iso T., Arzneim.-Forsch./Drug Res., 40, 244-248 (1990)
3. c) Miyawaki N., Furuta T., Shigei T., Yamauchi H., Iso T., J. Cardiovasc. Pharmacol., 16, 769-775 (1990)
4. d) Kageyama M., Nishimura K., Takada T., Miyawaki N., Yamauchi H , ibid., 17, 102-107 (1991)
5. e) Miyawaki N., Furuta T., Shigei T., Yamauchi H , Iso T., Life Sciences, 48, 1903-1909 (1991)
6. f)Takada T., Miyawaki N., Nishimura K., Nakata K., Matsuno K., Ishida N., Yamauchi H , Iso T., Arch. Int. Pharmacodyn., 309, 75-87 (1991)
7. g) Takada T., Miyawaki N., Kageyama M., Matsuno K., Ishida N., Yamauchi H., Iso T., J. Cardiovasc. Pharmacol., 18, 855-862 (1991)
8. h) Nakayama K., Nozawa Y., Fukuta Y., ibid., 23, 731-740(1994).
9. a)Ota A., Kawashima Y., Ohishi H., Ishida T., Chem. Pharm. Bull., 41, 1681-1685 (1993)
10. b) Ota A., Suhara H., Kawashima Y., ibid., 40, 833-836 (1992)
11. c) Fujimura K., Suhara H., Ota A., Kawashima Y., ibid., 40, 2901-2904 (1992)
12. d) Fujimura K., Fujita M., Suhara H., Kawashima Y., Bioorg. Med. Chem., 2, 235-242 (1994).
13. Mansch C., Leo A., Unger S. H., Kim K.-H., Nikaitani D., Lien E. J., J. Med. Chem., 16, 1207-1216 (1973); Hansch C., Rockwell S. D., Jow P. Y. C., Leo A., Steller E. E., ibid., 20, 304-306 (1977).
14. Mansch C., Leo A., Unger S. H., Kim K.-H., Nikaitani D., Lien E. J., J. Med. Chem., 16, 1207-1216 (1973); Hansch C., Rockwell S. D., Jow P. Y. C., Leo A., Steller E. E., ibid., 20, 304-306 (1977).
15. Leo A., Chem. Rev., 93, 1281-1306 (1993); BioByte Corp., 201 W. Fourth St., Suite #204, Claremont, California 91711.
16. Mannhold R., Bayer R., Ronsdorf M., Martens L., Arzenim.-Forsch./Drug Res., 37, 419-424 (1987); Mitani K., Yoshida T., Suzuki T., Koshinaka E., Kato H., Ito Y., Fujita T., Chem. Pharm. Bull., 36, 776-783 (1988); Mitani K., Sakurai S., Suzuki T., Morikawa K., Koshinaka E., Kato H., Ito Y., Fujita T., ibid, 36, 4103-4120 (1988).
17. Mannhold R., Bayer R., Ronsdorf M., Martens L., Arzenim.-Forsch./Drug Res., 37, 419-424 (1987); Mitani K., Yoshida T., Suzuki T., Koshinaka E., Kato H., Ito Y., Fujita T., Chem. Pharm. Bull., 36, 776-783 (1988); Mitani K., Sakurai S., Suzuki T., Morikawa K., Koshinaka E., Kato H., Ito Y., Fujita T., ibid, 36, 4103-4120 (1988).
18. Mannhold R., Bayer R., Ronsdorf M., Martens L., Arzenim.-Forsch./Drug Res., 37, 419-424 (1987); Mitani K., Yoshida T., Suzuki T., Koshinaka E., Kato H., Ito Y., Fujita T., Chem. Pharm. Bull., 36, 776-783 (1988); Mitani K., Sakurai S., Suzuki T., Morikawa K., Koshinaka E., Kato H., Ito Y., Fujita T., ibid, 36, 4103-4120 (1988).
19. 7)
20. b) Frisch M., Binkley J. S., Schlegel H. B., Raghavachari K., Martin R., Stewart J J. P., Bobrowicz F., Defrees D., Seeger R., Whiteside R., Fox D., Fluder E., Pople J. A., Gaussian-86 (Revision C), Gaussian, Inc., Carnegie Office Park Building 6, Pittsburgh, PA 15106.
21. Molecular Simulations Inc., 16 New England Executive Park, Burlington, Massachusetts 01803.